Patents Assigned to Naturex, S.A.
  • Patent number: 11590189
    Abstract: The present invention relates to extracts from Fraxinus angustifolia samara, processes for providing such extracts, and methods and uses of the extracts obtained. In particular, the present invention relates to the use of such extracts in reversing obesity-related and/or metabolic syndrome-related gut microbiota dysbiosis treatment, treating or preventing hepatic steatosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and modulating and/or adjusting gut microbiota.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: February 28, 2023
    Assignee: Naturex S.A.
    Inventors: Pascale Elizabeth Renée Fança-Berthon, Leila Denise Falcao, Antoine Charles Bily, Marc Roller, Simona Birtic
  • Patent number: 10934238
    Abstract: The invention relates to a novel organic solubilisation and/or extraction solvent comprising at least one compound selected from the group of saturated monocyclic terpenoids, to an extraction method using said solvent, and to extracts obtained by said method. More particularly, the invention relates to a novel use of para-menthane, a saturated terpenoid compound, as a solvent derived from natural substances, and also to a solvent comprising para-menthane.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: March 2, 2021
    Assignees: NATUREX, S.A., UNIVERSITE D'AVIGNON ET DES PAYS DE VAUCLUSE
    Inventors: Natacha Rombaut, Anne-Sylvie Fabiano Tixier, Simona Birtic, Antoine Charles Bily, Marc Roller, Farid Chemat
  • Patent number: 10604463
    Abstract: The invention relates to a novel organic solubilisation and/or extraction solvent comprising at least one compound selected from the group of saturated monocyclic terpenoids, to an extraction method using said solvent, and to extracts obtained by said method. More particularly, the invention relates to a novel use of para-menthane, a saturated terpenoid compound, as a solvent derived from natural substances, and also to a solvent comprising para-menthane.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: March 31, 2020
    Assignees: Naturex, S.A., Université d'Avignon et des Pays de Vaucluse
    Inventors: Natacha Rombaut, Anne-Sylvie Fabiano Tixier, Simona Birtic, Antoine Charles Bily, Marc Roller, Farid Chemat
  • Patent number: 10321695
    Abstract: A composition includes hesperdin and/or a Lamiaceae extract wherein a majority of the volatile components have been removed from the Lamiaceae extract. A method for applying the composition to a food such as meat, fish or poultry, including processed and fresh or unprocessed meat, poultry and fish is also provided.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 18, 2019
    Assignee: NATUREX S.A.
    Inventors: Simona Birtic, Mélanie Marie-Paule Patricia Heudre, François-Xavier Henri Pierre, Xavier Pierre François Mesnier, Anne Passemard, Antoine Charles Bily, Marc Roller
  • Patent number: 10219522
    Abstract: A composition includes Punica extract and a Lamiaceae extract, wherein a majority of the volatile oil components have been removed from the Lamiaceae extract. A method for applying the composition to a food which includes but is not limited to fresh/unprocessed and processed meat, fish or poultry is also provided.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: March 5, 2019
    Assignee: NATUREX S.A.
    Inventors: Mélanie Marie-Paule Patricia Heudré, Simona Birtic, François-Xavier Henri Pierre, Xavier Pierre François Mesnier, Anne Passemard, Antoine Charles Bily, Marc Roller
  • Patent number: 10092613
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: October 9, 2018
    Assignee: NATUREX, S.A.
    Inventors: Alvin Ibarra, Marc Roller, Jacques Dikansky
  • Patent number: 9956241
    Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total ginsenosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: May 1, 2018
    Assignee: Naturex, S.A.
    Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
  • Patent number: 9487552
    Abstract: The invention relates to a method for preparing a refined extract of Centella asiatica comprising a mixture of madecassoside and terminoloside. The method comprises: passage over adsorbent resin; elution with an eluent comprising at least 30 wt. % of an alcoholic solvent; and a recrystallization step using a mixture of solvents, comprising water and an alcoholic solvent.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: November 8, 2016
    Assignee: NATUREX, S.A.
    Inventor: Charles Duval
  • Publication number: 20160287655
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Application
    Filed: June 6, 2016
    Publication date: October 6, 2016
    Applicant: NATUREX, S.A.
    Inventors: Alvin IBARRA, Marc ROLLER, Jacques DIKANSKY
  • Patent number: 9358264
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Grant
    Filed: March 25, 2011
    Date of Patent: June 7, 2016
    Assignee: NATUREX, S.A.
    Inventors: Alvin Ibarra, Marc Roller, Jacques DiKansky
  • Publication number: 20160015766
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Application
    Filed: March 25, 2011
    Publication date: January 21, 2016
    Applicant: NATUREX, S.A.
    Inventors: Alvin IBARRA, Marc ROLLER, Jacques DIKANSKY
  • Publication number: 20150306119
    Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total ginsenosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.
    Type: Application
    Filed: February 27, 2015
    Publication date: October 29, 2015
    Applicant: NATUREX, S.A.
    Inventors: Andrew SCHOLEY, Alvin IBARRA, Kan HE, Marc ROLLER, Jacques DIKANSKY
  • Patent number: 9011936
    Abstract: Disclosed are methods of alleviating oxidative stress, regulating blood glucose levels, and controlling pancreatic lipase activity by administering a Rosemary extract. Such methods may be useful to help body weight and body fat, prevent obesity, and treat hyperglycemia, hyperinsulinemia, cardiovascular disease and Type-2 diabetes. Preferred extracts contain 20% or 50% carnosic acid.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: April 21, 2015
    Assignee: Naturex, S.A.
    Inventors: Kan He, Marc Roller, Alvin Ibarra, Naisheng Bai, Jacques DiKansky
  • Patent number: 8980342
    Abstract: A method of enhancing physical performance during exercise by administering an amount of a grape extract effective to treat a subject. A preferred grape extract comprises a concentration of flavanol monomers of greater than about 5% by weight, and more preferably within a range from about 12% by weight to about 50% by weight, and a concentration of flavanol dimers preferably greater than about 2% by weight, and more preferably within a range from about 6% by weight to about 20% by weight. The flavanol monomers preferably include catechin, epicatechin, epicatechin gallate, and gallic acid. The flavanol dimers preferably include procyanidin B1, procyanidin B2, procyanidin B3, procyanidin B4, and procyanidin B2-O-gallate.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: March 17, 2015
    Assignee: Naturex, S.A.
    Inventors: Benoit Lemaire, Sophie Lafay, Alvin Ibarra, Marc Roller, Jacques DiKansky
  • Publication number: 20150072042
    Abstract: A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach.
    Type: Application
    Filed: March 25, 2011
    Publication date: March 12, 2015
    Applicant: NATUREX, S.A.
    Inventors: Alvin IBARRA, Marc ROLLER, Jacques DiKANSKY
  • Patent number: 8968800
    Abstract: Disclosed are methods of enhancing neurocognitive function by administering of American Ginseng. Preferred dosages in the range of 5 to 50 mg total genosides enhance cognitive function—including, improvement of working memory (WM) performance, attentional performance (e.g., Choice Reaction Time accuracy), and calmness.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: March 3, 2015
    Assignee: Naturex, S.A.
    Inventors: Andrew Scholey, Alvin Ibarra, Kan He, Marc Roller, Jacques Dikansky
  • Patent number: 8293292
    Abstract: A Fraxinus excelsior seed extract that can be administered for therapeutic treatment of a subject, including a human, by blocking fat synthesis, activating PPAR-alpha, increasing hypoglycemic activity, reducing bodyweight, controlling fasting plasma insulin levels against hyperinsulinemia, and promoting insulin sensitivity and causing a beneficial acute insulinotropic effect. The Fraxinus excelsior seed extract includes, inter alia, an isolated compound (2S,3E,4S)2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)methyl ester, commonly called excelside A, an isolated compound (2S,3E,4S) 2H-Pyran-4-acetic acid-3-ethylidene-2-[(6-O-?-D-glucopyranosyl-?-D-glucopyranosyl)oxy]-3,4-dihydro-5-(methoxycarbonyl)2-(4-hydroxyphenyl)ethyl ester, commonly called excelside B, and the compounds GI5, GI3, nuzhenide, and oleoside dimethyl ester.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: October 23, 2012
    Assignee: Naturex, S.A.
    Inventors: Kan He, Marc Roller, Antoine Bily, Naisheng Bai, Jacques DiKansky, Alvin Ibarra